Harry Harvey
Overview
Explore the profile of Harry Harvey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
451
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harvey H, Chen E
J Gastrointest Oncol
. 2024 Sep;
15(4):1987-1992.
PMID: 39279930
No abstract available.
2.
Keogh R, Harvey H, Brady C, Hassett E, Costelloe S, OSullivan M, et al.
J Cancer Policy
. 2024 Jan;
39:100466.
PMID: 38176467
Introduction: Cyberattacks represent a growing threat for healthcare delivery globally. We assess the impact and implications of a cyberattack on a cancer center in Ireland. Methods: On May 14th 2021...
3.
Maguire J, Harvey H, Jones A, Law R, Bashir M, OBrien O, et al.
Histopathology
. 2023 Oct;
84(2):399-401.
PMID: 37876327
Aims: Large B-cell lymphoma with IRF4 rearrangement (LBCL-IRF4) is a recently described entity included in the revised 4th edition of the WHO Classification of Haematolymphoid Tumours (2017). Here we highlight...
4.
Macanovic B, OReilly D, Harvey H, Hadi D, Cloherty M, ODea P, et al.
Digit Health
. 2023 Jul;
9:20552076231185428.
PMID: 37426594
Purpose: To investigate the feasibility of implementing a remote patient monitoring system using an electronic patient-reported outcomes (ePROs) platform in a tertiary cancer center in the Republic of Ireland. Methods:...
5.
The Impact of a National Cyberattack Affecting Clinical Trials: The Cancer Trials Ireland Experience
Harvey H, Carroll H, Murphy V, Ballot J, OGrady M, OHare D, et al.
JCO Clin Cancer Inform
. 2023 Apr;
7:e2200149.
PMID: 37053539
Purpose: Cyberattacks are increasing in health care and cause immediate disruption to patient care, have a lasting impact, and compromise scientific integrity of affected clinical trials. On the May 14,...
6.
Abancens M, Bustos V, Harvey H, McBryan J, Harvey B
Front Oncol
. 2020 Dec;
10:607909.
PMID: 33363037
A higher incidence of colorectal cancer (CRC) is found in males compared to females. Young women (18-44 years) with CRC have a better survival outcome compared to men of the...
7.
Murphy C, Byrne S, Ahmed G, Kenny A, Gallagher J, Harvey H, et al.
Dose Response
. 2018 Oct;
16(4):1559325818803042.
PMID: 30288154
Background: Severe toxicity is experienced by a substantial minority of patients receiving fluoropyrimidine-based chemotherapy, with approximately 20% of these severe toxicities attributable to polymorphisms in the gene. The codes for...
8.
Bustos V, Nolan A, Nijhuis A, Harvey H, Parker A, Poulsom R, et al.
Oncotarget
. 2017 Nov;
8(48):84258-84275.
PMID: 29137421
The estrogen receptor ERβ is the predominant ER subtype expressed in normal well-differentiated colonic epithelium. However, ERβ expression is lost under the hypoxic microenvironment as colorectal cancer (CRC) malignancy progresses....
9.
Rapetti-Mauss R, Bustos V, Thomas W, McBryan J, Harvey H, Lajczak N, et al.
Proc Natl Acad Sci U S A
. 2017 Apr;
114(16):4159-4164.
PMID: 28373572
The K channel KCNQ1 has been proposed as a tumor suppressor in colorectal cancer (CRC). We investigated the molecular mechanisms regulating KCNQ1:β-catenin bidirectional interactions and their effects on CRC differentiation,...
10.
Piskareva O, Harvey H, Nolan J, Conlon R, Alcock L, Buckley P, et al.
Cancer Lett
. 2015 May;
364(2):142-55.
PMID: 25960282
Neuroblastoma is a challenging childhood malignancy, with a very high percentage of patients relapsing following acquisition of drug resistance, thereby necessitating the identification of mechanisms of drug resistance as well...